eviCore healthcare Clinical Decision Support Tool Diagnostic Strategies: This tool addresses common symptoms and symptom complexes. Imaging requests for individuals with atypical symptoms or clinical presentations that are not specifically addressed will require physician review. Consultation with the referring physician, specialist and/or individual’s Primary Care Physician (PCP) may provide additional insight.

eviCore’s Clinical Review Criteria (“CRC”) and related content is made available for the limited uses of: reference; and individual use, only limited to facilitating the determination of medically necessary and appropriate clinical treatment by clinicians for specific delegated patients under their care. The CRC and related content is proprietary information of eviCore, and copyrighted to the full extent of the law. Except as expressly permitted, you may not modify, copy, reproduce, republish, upload, post, transmit, hyperlink to or from, or distribute in any way the CRC, nor may you sell, transfer, distribute, assign, lease, reproduce, or otherwise use the CRC in commerce, in a manner that competes with us or infringes upon our rights, or for any public or commercial endeavor without our prior and express written consent.

CPT® (Current Procedural Terminology) is a registered trademark of the American Medical Association (AMA). CPT® five digit codes, nomenclature and other data are copyright 2023 American Medical Association. All Rights Reserved. No fee schedules, basic units, relative values or related listings are included in the CPT® book. AMA does not directly or indirectly practice medicine or dispense medical services. AMA assumes no liability for the data contained herein or not contained herein.

©2023 eviCore healthcare. All rights reserved.
# Table of Contents

<table>
<thead>
<tr>
<th>Guideline</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Guideline Development (Preface-1)</td>
<td>3</td>
</tr>
<tr>
<td>Benefits, Coverage Policies, and Eligibility Issues (Preface-2)</td>
<td>5</td>
</tr>
<tr>
<td>Clinical Information (Preface-3)</td>
<td>8</td>
</tr>
<tr>
<td>Coding Issues (Preface-4)</td>
<td>18</td>
</tr>
<tr>
<td>Whole-Body Imaging (Preface-5)</td>
<td>32</td>
</tr>
<tr>
<td>References (Preface-6)</td>
<td>37</td>
</tr>
<tr>
<td>Copyright Information (Preface-7)</td>
<td>39</td>
</tr>
<tr>
<td>Trademarks (Preface-8)</td>
<td>41</td>
</tr>
</tbody>
</table>
Guideline Development (Preface-1)

<table>
<thead>
<tr>
<th>Guideline</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Guideline Development (Preface-1.1)</td>
<td>4</td>
</tr>
</tbody>
</table>
Guideline Development (Preface-1.1)

The eviCore healthcare (eviCore) evidence-based, proprietary clinical guidelines evaluate a range of advanced imaging and procedures, including NM, US, CT, MRI, PET, Radiation Oncology, Sleep Studies, Gastrointestinal Endoscopy, as well as Cardiac, musculoskeletal and Spine interventions.

eviCore reserves the right to change and update the guidelines. The guidelines undergo a formal review annually. eviCore’s guidelines are based on current evidence supported by major national and international association and society guidelines and criteria, peer-reviewed literature, major treatises as well as, input from health plans, and practicing academic and community-based physicians.

These guidelines are not intended to supersede or replace sound medical judgment, but instead, should facilitate the identification of the most appropriate imaging or other designated procedure given the individual’s clinical condition. These guidelines are written to cover medical conditions as experienced by the majority of individuals. However, these guidelines may not be applicable in certain clinical circumstances, and physician judgment can override the guidelines.

These guidelines provide evidence-based, clinical benefits with a focus on health care quality and patient safety.

Clinical decisions, including treatment decisions, are the responsibility of the individual and his/her provider. Clinicians are expected to use independent medical judgment, which takes into account the clinical circumstances to determine individual management decisions.

eviCore supports the Choosing Wisely initiative (https://www.choosingwisely.org/) by the American Board of Internal Medicine (ABIM) Foundation and many national physician organizations, to reduce the overuse of diagnostic tests that are low value, no value, or whose risks are greater than the benefits.
<table>
<thead>
<tr>
<th>Guideline</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benefits, Coverage Policies, and Eligibility Issues</td>
<td>6</td>
</tr>
<tr>
<td>(Preface-2.1)</td>
<td></td>
</tr>
<tr>
<td>References (Preface-2)</td>
<td>7</td>
</tr>
</tbody>
</table>
Benefits, coverage policies, and eligibility issues pertaining to each Health Plan may take precedence over eviCore's guidelines. Providers are urged to obtain written instructions and requirements directly from each payor.

**Medicare Coverage Policies**

- See eviCore's *Medicaid and Medicare Hierarchy and Application*

**Investigational and Experimental Studies**

- See eviCore's *Guideline Definitions*

**Clinical and Research Trials**

- Similar to investigational and experimental studies, clinical trial imaging requests will be considered to determine whether they meet Health Plan coverage and eviCore's evidence-based guidelines.
- Imaging studies which are inconsistent with established clinical standards, or are requested for data collection and not used in direct clinical management are not supported³.

**Legislative Mandate**

- State and federal legislations may need to be considered in the review of advanced imaging requests. For example:
  - Various State and Federal Breast Density Laws
  - Texas HB 1290 Coronary Calcium CT Law
1. Prospective Payment Systems - General Information. CMS. 
   %20Payment%20System%20(PPS,on%20a%20predetermined%2C%20fixed%20amount.
<table>
<thead>
<tr>
<th>Guideline</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Information (Preface-3.1)</td>
<td>9</td>
</tr>
<tr>
<td>References (Preface-3)</td>
<td>17</td>
</tr>
</tbody>
</table>
Clinical Documentation and Age Considerations

• eviCore guidelines use an evidence-based approach to determine the most appropriate procedure for each individual, at the most appropriate time in the diagnostic and treatment cycle. eviCore guidelines are framed by:
  o Clinical presentation of the individual, rather than the studies requested
  o Adequate clinical information that must be submitted to eviCore in order to establish medical necessity for advanced imaging or other designated procedures includes, but is not limited to the following:
    ▪ Pertinent clinical evaluation should include a recent detailed history, physical examination\(^{20}\) since the onset or change in symptoms, and/or laboratory and prior imaging studies.
    • Condition-specific guideline sections may describe additional clinical information which is required for a pertinent clinical evaluation.
    • The Spine and Musculoskeletal guidelines require x-ray studies from when the current episode of symptoms has started or changed; x-ray imaging does not have to be within the past 60 days.
    • Advanced imaging or other designated procedures should not be ordered prior to clinical evaluation of an individual by the physician treating the individual. This may include referral to a consultant specialist who will make further treatment decisions.
    • Other meaningful technological contact (telehealth visit, telephone or video call, electronic mail or messaging) since the onset or change in symptoms by an established individual can serve as a pertinent clinical evaluation.
    • Some conditions may require a face-to-face evaluation as discussed in the applicable condition-specific guideline sections.
    ▪ A recent clinical evaluation may be unnecessary if the individual is undergoing a guideline-supported, scheduled follow-up imaging or other designated procedural evaluation. Exceptions due to routine surveillance indications are addressed in the applicable condition-specific guideline sections.
      o eviCore’s evidence-based approach to determine the most appropriate procedure for each individual requires submission of medical records pertinent to the requested imaging or other designated procedures.
  • Many conditions affecting the pediatric population are different diagnoses than those occurring in the adult population. For those diseases which occur in both pediatric and adult populations, minor differences may exist in management due to individual age, comorbidities, and differences in disease natural history between children and adults.
Individuals who are 18 years old or younger should be imaged according to the Pediatric Imaging Guidelines if discussed in the condition-specific guideline sections. Any conditions not specifically discussed in the Pediatric Imaging Guidelines should be imaged according to the General Imaging Guidelines. Individuals who are >18 years old should be imaged according to the General Imaging Guidelines, except where directed otherwise by a specific guideline section.

- The terms “male” and “female” used in these guidelines refer to anatomic-specific diseases and disease predispositions associated with the individual’s sex assigned at birth rather than their gender identity. It should be noted that gender identity and anatomic-specific diseases as well as disease predispositions are not always linked. As such, these guidelines should be applied to the individual’s corresponding known or suspected anatomic-specific disease or disease predisposition. At eviCore, we believe that it is important to understand how all individuals, including those who are gender-diverse, choose to identify themselves. To ensure that gender-diverse individuals are treated with respect and that decisions impacting their healthcare are made correctly and with sensitivity, eviCore recognizes all individuals with the following gender marker options: Male, Female, Transgender Male, Transgender Female, “X”, and “Not Specified.”

General Imaging Information

- “Standard” or “conventional” imaging is most often performed in the initial and subsequent evaluations of malignancy. Standard or conventional imaging includes plain film, CT, MRI, or US.
  - Often, further advanced imaging is needed when initial imaging, such as ultrasound, CT, or MRI does not answer the clinical question. Uncertain, indeterminate, inconclusive, or equivocal may describe these situations.
- Appropriate use of contrast is a very important component of evidence-based advanced imaging use.
  - The appropriate levels of contrast for an examination (i.e., without contrast, with contrast, without and with contrast) is determined by the evidence-based guidance reflected in the condition-specific guideline sections.
  - If, during the performance of a non-contrast imaging study, there is the unexpected need to use contrast in order to evaluate a possible abnormality, then that is appropriate.¹

Ultrasound

- Diagnostic ultrasound uses high-frequency sound waves to evaluate soft tissue structures and vascular structures utilizing grey scale and Doppler techniques.
- Ultrasound allows for dynamic real-time imaging at the bedside.
  - Ultrasound is limited in areas where there is dense bone or other calcification.
  - Ultrasound also has a relatively limited imaging window so may be of limited value in evaluating very large abnormalities.
  - In general, ultrasound is highly operator-dependent, and proper training and experience are required to perform consistent, high-quality evaluations.
• Indications for ultrasound may include, but are not limited to, the following:
  o Obstetric and gynecologic imaging
  o Soft tissue and visceral imaging of the chest, abdomen, pelvis, and extremities
  o Brain and spine imaging when not obscured by dense bony structures
  o Vascular imaging when not obscured by dense bony structures
  o Procedural guidance when not obscured by dense bony structures
  o Initial evaluation of ill-defined soft tissue masses or fullness and differentiating adenopathy from mass or cyst. Prior to advanced imaging, ultrasound can be very beneficial in selecting the proper modality, body area, image sequences, and contrast level that will provide the most definitive information for the individual.
• More specific guidance for ultrasound usage, including exceptions to this general guidance, can be found throughout the condition-specific guidelines.

Computed Tomography (CT)
• The AMA CPT® manual does not describe nor assign any minimum or maximum number of sequences for any CT study. CT imaging protocols are often influenced by the individual's clinical situation and additional sequences are not uncommon. There are numerous CT protocols that may be performed to evaluate specific clinical questions, and this technology is constantly undergoing development.
• CT utilizes ionizing radiation to create cross-sectional and volumetric images of the body.
  o Advantages over ultrasound include a much larger field of view and faster completion time in general. Disadvantages compared to ultrasound include lack of portability and exposure to ionizing radiation.
  o Advantages over MRI include faster imaging and a more spacious scanner area limiting claustrophobia. Disadvantages compared to MRI include decreased soft tissue definition, especially with non-contrast imaging, and exposure to ionizing radiation.
• CT can be performed without, with, or without and with intravenous (IV) contrast depending on the clinical indication and body area.
  o In general, non-contrast imaging is appropriate for evaluating structures with significant tissue density differences such as lung parenchyma and bony structures, or when there is a contraindication to contrast.
  o In general, CT with contrast is the most common level of contrast and can be used when there is need for improved vascular or soft tissue resolution, including better characterization of known or suspected malignancy as well as infectious and inflammatory conditions.
  o CT without and with contrast has a limited role as the risks of doubling the ionizing radiation exposure rarely outweigh the benefits of multiphasic imaging, though there are some exceptions which include, but are not limited to, the following:
    ▪ Characterization of a mass
    ▪ Characterization of arterial and venous anatomy
- CT with contrast may be used to better characterize findings on a very recent (within two weeks) inconclusive non-contrast CT where the guidelines would support CT without and with contrast.
  - More specific guidance for CT contrast usage, including exceptions to this general guidance, can be found throughout the condition-specific guidelines.

- Shellfish allergy:
  - It is commonly assumed that an allergy to shellfish indicates iodine allergy, and that this implies an allergy to iodinated contrast media used with CT. However, this is NOT true. Shellfish allergy is due to tropomyosins. Iodine plays no role in these allergic reactions. Allergies to shellfish do not increase the risk of reaction to iodinated contrast media any more than that of other allergens.\(^1\)

- Enteric contrast (oral or rectal) is sometimes used in abdominal imaging. There is no specific CPT\(^\text{®}\) code which refers to enteric contrast.

- The appropriate contrast level and anatomic region in CT imaging is specific to the clinical indication, as listed in the condition-specific guideline sections.

- CT should not be used to replace MRI in an attempt to avoid sedation unless it is listed as a recommended study the appropriate condition-specific guideline.

- There are significant potential adverse effects associated with the use of iodinated contrast media. These include hypersensitivity reactions, thyroid dysfunction, and contrast-induced nephropathy (CIN). Individuals with impaired renal function are at increased risk for CIN.\(^2\)

- Both contrast CT and MRI may be considered to have the same risk profile with renal failure (GFR <30 mL/min).

- The use of CT contrast should proceed with caution in pregnant and breastfeeding individuals. There is a theoretical risk of contrast toxicity to the fetal and infant thyroid. The procedure can be performed if the specific need for that contrast-enhanced procedure outweighs risk to the fetus. Breastfeeding individuals may reduce this risk by choosing to pump and discard breast milk for 12-24 hours after the contrast injection.

- CT without contrast may be appropriate if clinical criteria for CT with contrast are met AND the individual has:
  - Elevated blood urea nitrogen (BUN) and/or creatinine
  - Renal insufficiency
  - Allergies to iodinated contrast
  - Thyroid disease which could be treated with I-131
  - Diabetes
  - Very elderly
  - Urgent or emergent settings due to availability
  - Trauma

- CT is superior to other imaging modalities in certain conditions including, but not limited to, the following:
  - Screening following trauma
  - Imaging pulmonary disease
Imaging abdominal and pelvic viscera
Imaging of complex fractures
Evaluation of inconclusive findings on Ultrasound or MRI, or if there is a contraindication to MRI

- More specific guidance for CT usage, including exceptions to this general guidance, can be found throughout the condition-specific guidelines.

**Magnetic Resonance Imaging (MRI)**

- The AMA CPT® manual does not describe nor assign any minimum or maximum number of sequences for any MRI study. MRI protocols are often influenced by the individual’s clinical situation and additional sequences are not uncommon. There are numerous MRI sequences that may be performed to evaluate specific clinical questions, and this technology is constantly undergoing development.
- Magnetic Resonance Imaging (MRI) utilizes the interaction between the intrinsic radiofrequency of certain molecules in the body (hydrogen in most cases) and a strong external magnetic field.
  - MRI is often superior for advanced imaging of soft tissues and can also define physiological processes in some instances (e.g., edema, loss of circulation [AVN], and increased vascularity [tumors]).
  - MRI does not use ionizing radiation, and even non-contrast images have much higher soft tissue definition than CT or Ultrasound.
  - MRI typically takes much longer than either CT or Ultrasound, and for some individuals may require sedation. It is also much more sensitive to individual motion that can degrade image quality than either CT or Ultrasound.
- MRI Breast and MRI Chest are not interchangeable, as they focus detailed sequences on different adjacent body parts.
- MRI may be utilized either as the primary advanced imaging modality, or when further definition is needed based on CT or ultrasound imaging.
- Most orthopedic and dental implants are not magnetic. These include hip and knee replacements; plates, screws, and rods used to treat fractures; and cavity fillings. Yet, all of these metal implants can distort the MRI image if near the part of the body being scanned.
  - Other implants, however, may have contraindications to MRI. These include the following:
    - Pacemakers
    - ICD or heart valves
    - Metal implants in the brain
    - Metal implants in the eyes or ears
    - Infusion catheters and bullets or shrapnel
  - CT can therefore be an alternative study to MRI in these scenarios.
- The contrast level and anatomic region in MRI imaging is specific to the clinical indication, as listed in the specific guideline sections.
• MRI utilizing Xenon Xe 129 for contrast is considered investigational and experimental at this time. MRI with or with and without contrast in these guidelines refers to MRI utilizing gadolinium for contrast.

• MRI is commonly performed without, without and with contrast.
  o Non-contrast imaging offers excellent tissue definition.
  o Imaging without and with contrast is commonly used when needed to better characterize tissue perfusion and vascularization.
    ▪ Most contrast is gadolinium based and causes T2 brightening of the vascular and extracellular spaces.
    ▪ Some specialized gadolinium and non-gadolinium contrast agents are available, and most commonly used for characterizing liver lesions.
  o MRI with contrast only is rarely appropriate and is usually used to better characterize findings on a recent inconclusive non-contrast MRI, commonly called a completion study.
  o MRI contrast is contraindicated in pregnant individuals.
  o More specific guidance for MRI contrast usage, including exceptions to this general guidance, can be found throughout the condition-specific guidelines.

• MRI may be preferred in individuals with renal failure and in individuals allergic to intravenous CT contrast.
  o Both contrast CT and MRI may be considered to have the same risk profile with renal failure (GFR <30 mL/min). The greater the exposure to gadolinium in individuals with a low GFR (especially if on dialysis), the greater the chance of individuals developing NSF.
  o Gadolinium can cause Nephrogenic Systemic Fibrosis (NSF). The greater the exposure to gadolinium in individuals with a low GFR (especially if on dialysis), the greater the chance of individuals developing NSF.
  o Multiple studies have demonstrated potential for gadolinium deposition following the use of gadolinium-based contrast agents (GBCAs) for MRI studies. The U.S. Food and Drug Administration (FDA) has noted that there is currently no evidence to suggest that gadolinium retention in the brain is harmful and restricting gadolinium-based contrast agents (GBCAs) use is not warranted at this time. It has been recommended that GBCA use should be limited to circumstances in which additional information provided by the contrast agent is necessary and the necessity of repetitive MRIs with GBCAs should be assessed.

• A CT may be approved in place of an MRI when clinical criteria are met for MRI AND there is a contraindication to having an MRI (pacemaker, ICD, insulin pump, neurostimulator, etc.).
  o When replacing MRI with CT, contrast level matching should occur as follows:
    ▪ MRI without contrast → CT without contrast
    ▪ MRI without and with contrast → CT with contrast or CT without and with contrast

• The following situations may impact the appropriateness for MRI and or MR contrast:
  o Caution should be taken in the use of gadolinium in individuals with renal failure.
o The use of gadolinium contrast agents is contraindicated during pregnancy unless the specific need for that procedure outweighs risk to the fetus.

o MRI can be performed for non-ferromagnetic body metals (i.e., titanium), although some imaging facilities will consider it contraindicated if recent surgery, regardless of the metal type.

• MRI should not be used as a replacement for CT for the sole reason of avoidance of ionizing radiation when MRI is not supported in the condition-based guidelines, since it does not solve the problem of overutilization.

• MRI is superior to other imaging modalities in certain conditions including, but not limited to, the following:
  o Imaging the brain and spinal cord
  o Characterizing visceral and musculoskeletal soft tissue masses
  o Evaluating musculoskeletal soft tissues including ligaments and tendons
  o Evaluating inconclusive findings on ultrasound or CT
  o Individuals who are pregnant or have high radiation sensitivity
  o Suspicion, diagnosis, or surveillance of infections

• More specific guidance for MRI usage, including exceptions to this general guidance, can be found throughout the condition-specific guidelines.

Positron Emission Tomography (PET)

• PET is a nuclear medicine study that uses a positron emitting radiotracer to create cross-sectional and volumetric images based on tissue metabolism.

• Conventional imaging (frequently CT, sometimes MRI or bone scan) of the affected area(s) drives much of initial and restaging and surveillance imaging for malignancy and other chronic conditions. PET is not indicated for surveillance imaging unless specifically stated in the condition-specific guideline sections.

• PET/MRI is generally not supported, see PET-MRI (Preface-5.3).

• PET is rarely performed as a single modality, but is typically performed as a combined PET/CT.
  o The unbundling of PET/CT into separate PET and diagnostic CT CPT® codes is not supported, because PET/CT is done as a single study.

• PET/CT lacks the tissue definition of CT or MRI, but is fairly specific for metabolic activity based on the radiotracer used.

• Indications for PET/CT may include the following:
  o Oncologic Imaging for evaluation of tumor metabolic activity
  o Cardiac Imaging for evaluation of myocardial metabolic activity
  o Brain Imaging for evaluation of metabolic activity for procedural planning

• More specific guidance for PET usage, including exceptions to this general guidance, can be found throughout the condition-specific guidelines.

Overutilization of Advanced Imaging

• A number of recent reports describe overutilization in many areas of advanced imaging and other procedures, which may include the following:
o High-level testing without consideration of less invasive, lower cost options which may adequately address the clinical question at hand
o Excessive radiation and costs with unnecessary testing
o Defensive medical practice
o CT without and with contrast (so called “double contrast studies”) requests, which have few current indications
o MRI requested in place of CT to avoid radiation without considering the primary indication for imaging
o Adult CT settings and protocols used for smaller people and children
o Unnecessary imaging procedures when the same or similar studies have already been conducted

• A review of the imaging or other relevant procedural histories of all individuals presenting for studies has been recognized as one of the more important processes that can be significantly improved. By recognizing that a duplicate or questionably indicated examination has been ordered for individuals, it may be possible to avoid exposing them to unnecessary risks. To avoid these unnecessary risks, the precautions below should be considered:

  o The results of initial diagnostic tests or radiologic studies to narrow the differential diagnosis should be obtained prior to performing further tests or radiologic studies.
  o The clinical history should include a potential indication such as a known or suspected abnormality involving the body part for which the imaging study is being requested. These potential indications are addressed in greater detail within the applicable guidelines.
  o The results of the requested imaging procedures should be expected to have an impact on individual management or treatment decisions.
  o Repeat imaging studies are not generally necessary unless there is evidence of disease progression, recurrence of disease, and/or the repeat imaging will affect an individual’s clinical management.

• Pre-operative imaging/pre-surgical planning imaging/pre-procedure imaging is considered not medically necessary if the surgery/procedure is not considered medically necessary. Once the procedure has been approved or if the procedure does not require prior authorization, the appropriate pre-procedural imaging may be approved.
References (Preface-3)


8. FDA Warns That Gadolinium-Based Contrast Agents (GBCAs) Are Retained in the Body; Requires New Class Warnings. https://www.fda.gov/media/109825/download.


<table>
<thead>
<tr>
<th>Guideline</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>3D Rendering (Preface-4.1)</td>
<td>19</td>
</tr>
<tr>
<td>CT-, MR-, or Ultrasound-Guided Procedures (Preface-4.2)</td>
<td>21</td>
</tr>
<tr>
<td>Unlisted Procedures/Therapy Treatment Planning (Preface-4.3)</td>
<td>24</td>
</tr>
<tr>
<td>Unilateral Versus Bilateral Breast MRI (Preface-4.4)</td>
<td>25</td>
</tr>
<tr>
<td>CPT® 76380 Limited or Follow-up CT (Preface-4.5)</td>
<td>26</td>
</tr>
<tr>
<td>SPECT/CT Imaging (Preface-4.6)</td>
<td>27</td>
</tr>
<tr>
<td>CPT® 76140 Interpretation of an Outside Study (Preface-4.7)</td>
<td>28</td>
</tr>
<tr>
<td>Quantitative MR Analysis of Tissue Composition (Preface-4.8)</td>
<td>29</td>
</tr>
<tr>
<td>HCPCS Codes (Preface-4.9)</td>
<td>30</td>
</tr>
<tr>
<td>References (Preface-4)</td>
<td>31</td>
</tr>
</tbody>
</table>
3D Rendering (Preface-4.1)

CPT® 76376 and CPT® 76377

• Both codes require concurrent supervision of the image post-processing 3D manipulation of the volumetric data set and image rendering.
  o Concurrent supervision is defined as active physician participation in and monitoring of the reconstruction process including design of the anatomic region that is to be reconstructed; determination of the tissue types and actual structures to be displayed (e.g., bone, organs, and vessels); determination of the images or cine loops that are to be archived; and monitoring and adjustment of the 3D work product. The American College of Radiology (ACR) recommends that it is best to document the physician’s supervision or participation in the 3D reconstruction of images.
  
• These two codes differ in the need for and use of an independent workstation for post-processing.
  o CPT® 76376 reports procedures not requiring image post-processing on an independent workstation.
  o CPT® 76377 reports procedures that require image post-processing on an independent workstation.

• These 3D rendering codes should not be used for 2D reformatting.

• Two-dimensional reconstruction (e.g., reformatting an axial scan into the coronal plane) is now included in all cross-sectional imaging base codes and is not separately reimbursable.

• Some payors do not reimburse separately for CPT® 76376 or CPT® 76377. In addition, these CPT® codes are not included in every eviCore individual's radiology management program.
  o The codes used to report 3D rendering for ultrasound and echocardiography are also used to report the 3D post processing work on CT, MRI, and other tomographic modalities.

• Providers may be required to obtain prior authorization on these 3D codes even if prior authorization is not required for the echocardiography and/or ultrasound procedure codes. It may appear that eviCore pre-authorizes echocardiography and/or ultrasound when, in fact, it may only be the 3D code that needs the prior authorization.
  o Prior authorization requirements are established on a CPT® code level and vary by the individual health plan payor.
  o Providers are urged to obtain written instructions and requirements directly from each payor.

• CPT® codes for 3D rendering should not be billed in conjunction with computer-aided detection (CAD), MRA, CTA, nuclear medicine SPECT studies, PET, PET/CT,
Mammogram, MRI Breast, US Breast, CT Colonography (virtual colonoscopy), Cardiac MRI, Cardiac CT, or Coronary CTA studies.

- CPT® 76377 (3D rendering requiring image post-processing on an independent workstation) or CPT® 76376 (3D rendering not requiring image post-processing on an independent workstation) can be considered in the following clinical scenarios:
  o Bony conditions:
    - Evaluation of congenital skull abnormalities in newborns, infants, and toddlers (usually for pre-operative planning)
    - Complex fractures (comminuted or displaced)/dislocations of any joint (for pre-operative planning when conventional imaging is insufficient)
    - Spine fractures, pelvic/acetabulum fractures, intra-articular fractures (for pre-operative planning when conventional imaging is insufficient)
    - Pre-operative planning for other complex surgical cases
    - Complex facial fractures
  o Preoperative planning for other complex surgical cases
  o Cerebral angiography
  o Pelvis conditions:
    - Uterine intra-cavitary lesion when initial US is equivocal: See Abnormal Uterine Bleeding (AUB) (PV-2.1) and Leiomyoma/Uterine Fibroids (PV-12.1) in the Pelvis Imaging Guidelines.
    - Hydrosalpinxes or peritoneal cysts when initial US is indeterminate: See Complex Adnexal Masses (PV-5.3) in the Pelvis Imaging Guidelines.
    - Lost IUD (inability to feel or see IUD string) with initial US: See Intrauterine Device (PV-10.1) in the Pelvis Imaging Guidelines.
  o Abdomen conditions:
CT-, MR-, or Ultrasound-Guided Procedures (Preface-4.2)

CT-, MR-, and Ultrasound-guidance procedure codes contain all of the imaging necessary to guide a needle or catheter. It is inappropriate to routinely bill a diagnostic procedure code in conjunction with a guidance procedure code.

Imaging studies performed as part of a CT-, MR-, or Ultrasound-guided procedure should be reported using the CPT® codes in the following table:

<table>
<thead>
<tr>
<th>CPT®</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>19085</td>
<td>Biopsy, breast, with placement of breast localization device(s), when performed, and imaging of the biopsy specimen, when performed, percutaneous; first lesion, including MR guidance</td>
</tr>
<tr>
<td>19086</td>
<td>Biopsy, breast, with placement of breast localization device(s), when performed, and imaging of the biopsy specimen, when performed, percutaneous; each additional lesion, including MR guidance</td>
</tr>
<tr>
<td>75989</td>
<td>Imaging guidance for percutaneous drainage with placement of catheter (all modalities)</td>
</tr>
<tr>
<td>76942</td>
<td>Ultrasonic guidance for needle placement</td>
</tr>
<tr>
<td>77011</td>
<td>CT guidance for stereotactic localization</td>
</tr>
<tr>
<td>77012</td>
<td>CT guidance for needle placement</td>
</tr>
<tr>
<td>77013</td>
<td>CT guidance for, and monitoring of parenchymal tissue ablation</td>
</tr>
<tr>
<td>77021</td>
<td>MR guidance for needle placement</td>
</tr>
<tr>
<td>77022</td>
<td>MR guidance for, and monitoring of parenchymal tissue ablation</td>
</tr>
</tbody>
</table>

CPT® 19085 and CPT® 19086

The proper way to bill an MRI-guided breast biopsy is CPT® 19085 (Biopsy, breast, with placement of breast localization device(s), when performed, and imaging of the biopsy specimen, when performed, percutaneous; first lesion, including MR guidance). Additional lesions should be billed using CPT® 19086.

- **CPT® 77021** (MR guidance for needle placement) is not an appropriate code for a breast biopsy.

CPT® 75989

This code is used to report imaging guidance for a percutaneous drainage procedure in which a catheter is left in place.
• This code can be used to report whether the drainage catheter is placed under fluoroscopy, Ultrasound-, CT-, or MR-guidance modality.

**CPT® 77011**

• A stereotactic CT localization scan is frequently obtained prior to sinus surgery. The dataset is then loaded into the navigational workstation in the operating room for use during the surgical procedure. The information provides exact positioning of surgical instruments with regard to the individual’s 3D CT images.³

• In most cases, the pre-operative CT is a technical-only service that does not require interpretation by a radiologist.
  o The imaging facility should report CPT® 77011 when performing a scan not requiring interpretation by a radiologist.
  o If a diagnostic scan is performed and interpreted by a radiologist, the appropriate diagnostic CT code (e.g., CPT® 70486) should be used.
  o It is not appropriate to report both CPT® 70486 and CPT® 77011 for the same CT stereotactic localization imaging session.
  o 3D Rendering (CPT® 76376 or CPT® 76377) should not be reported in conjunction with CPT® 77011 (or CPT® 70486 if used). The procedure inherently generates a 3D dataset.

**CPT® 77012 (CT) and CPT® 77021 (MR)**

• These codes are used to report imaging guidance for needle placement during biopsy, aspiration, and other percutaneous procedures.

• They represent the radiological supervision and interpretation of the procedure and are often billed in conjunction with surgical procedure codes.
  o For example, CPT® 77012 is reported when CT guidance is used to place the needle for a conventional arthrogram.
  o Only codes representing percutaneous surgical procedures should be billed with CPT® 77012 and CPT® 77021. It is inappropriate to use with surgical codes for open, excisional, or incisional procedures.
  o **CPT® 77021** (MR guidance for needle placement) is not an appropriate code for breast biopsy.
    ▪ CPT® 19085 would be appropriate for the first breast biopsy site and CPT® 19086 would be appropriate for additional concurrent biopsies.

**CPT® 77013 (CT) and CPT® 77022 (MR)**

• These codes include the initial guidance to direct a needle electrode to the tumor(s), monitoring for needle electrode repositioning within the lesion, and as necessary for multiple ablations to coagulate the lesion and confirmation of satisfactory coagulative necrosis of the lesion(s) and comparison to pre-ablation images.
  o **NOTE** : CPT® 77013 should only be used for non-bone ablation procedures.
    ▪ CPT® 20982 includes CT guidance for bone tumor ablations.
Only codes representing percutaneous surgical procedures should be billed with CPT® 77013 and CPT® 77022. It is inappropriate to use with surgical codes for open, excisional, or incisional procedures.

- CPT® 77012 and CPT® 77021 (as well as guidance codes CPT® 76942 [US] and CPT® 77002 - CPT® 77003 [fluoroscopy]) describe radiologic guidance by different modalities.

- Only one unit of any of these codes should be reported per individual encounter (date of service). The unit of service is considered to be the individual encounter, not the number of lesions, aspirations, biopsies, injections, or localizations.
Unlisted Procedures/Therapy Treatment Planning (Preface-4.3)

CPT® Description
76497 Unlisted CT procedure (e.g., diagnostic or interventional)
76498 Unlisted MR procedure (e.g., diagnostic or interventional)
78999 Unlisted procedure, diagnostic nuclear medicine

- In the absence of written payor instructions, these unlisted codes should be reported whenever a diagnostic or interventional CT or MR study is performed in which an appropriate anatomic site-specific code is not available.
  - A Category III code that describes the procedure performed must be reported rather than an unlisted code if one is available.
- CPT® 76497 or CPT® 76498 (Unlisted CT or MRI procedure) can be considered in the following clinical scenarios:
  - Studies done for navigation and planning for neurosurgical procedures (i.e., Stealth or Brain Lab Imaging)¹²
  - Custom joint arthroplasty planning if covered by payor (not as an alternative recommendation): See Osteoarthritis (MS-12.1) in the Musculoskeletal Imaging Guidelines.
  - Any procedure/surgical planning if thinner cuts or different positional acquisition (than those on the completed diagnostic study) are needed. These could include navigational bronchoscopy: See Navigational Bronchoscopy (CH-1.7) in the Chest Imaging Guidelines.

Therapy Treatment Planning
- Radiation Therapy Treatment Planning: See Unlisted Procedure Codes in Oncology (ONC-1.5) in the Oncology Imaging Guidelines.
Unilateral Versus Bilateral Breast MRI
(Preface-4.4)

- Diagnostic MRI of both breasts should be coded as CPT® 77049 regardless of whether both breasts are imaged simultaneously or whether unilateral breast MRI is performed in two separate imaging sessions.
CPT® 76380 Limited or Follow-up CT (Preface-4.5)

- CPT® 76380 describes a limited or follow-up CT scan. The code is used to report any CT scan, for any given area of the body, in which the work of a full diagnostic code is not performed.

- Common examples include, but are not limited to, the following:
  - Limited sinus CT imaging protocol
  - Limited or follow-up slices through a known pulmonary nodule
  - Limited slices to assess a non-healing fracture (such as the clavicle)

- Limited CT (CPT® 76380) is not indicated for treatment planning purposes. See Unlisted Procedure Codes in Oncology (ONC-1.5) in the Oncology Imaging Guidelines.

- It is inappropriate to report CPT® 76380, in conjunction with other diagnostic CT codes, to cover ‘extra slices’ in certain imaging protocols.
  - There is no specific number of sequences or slices defined in any CT CPT® code definition.
  - The AMA, in CPT® 2019, does not describe nor assign any minimum or maximum number of sequences or slices for any CT study.
    - A few additional slices or sequences are not uncommon.
    - CT imaging protocols are often influenced by the individual's clinical situation. Sometimes the protocols require more time and sometimes less.
SPECT/CT Imaging (Preface-4.6)

- SPECT/CT involves SPECT (Single Photon Emission Computed Tomography) nuclear medicine imaging and CT for optimizing location, accuracy, and attenuation correction and combines functional and anatomic information.
  - Common studies using this modality include $^{123}$I- or $^{131}$I-Metaiodobenzylguanidine (MIBG) and octreotide scintigraphy for neuroendocrine tumors.

- Hybrid Nuclear/CT scan can be reported as CPT® 78830 (single area and single day), CPT® 78831 (2 or more days), or CPT® 78832 (2 areas with one day and 2 day study).

- CPT® 78072 became effective January 1, 2013 for SPECT/CT parathyroid nuclear imaging.
CPT® 76140 Interpretation of an Outside Study (Preface-4.7)

PRF.CD.0004.7.A
v3.0.2023

- It is inappropriate to use diagnostic imaging codes for interpretation of a previously performed exam that was completed at another facility.
  - If the outside exam is being used for comparison with a current exam, the diagnostic code for the current examination includes comparison to the prior study.  
  - CPT® 76140 is the appropriate code to use for an exam which was completed elsewhere and a secondary interpretation of the images is requested.  
    - Medicare, as well as many other payors do not reimburse CPT® 76140 and their coverage policies take precedence over eviCore’s guidelines.
Quantitative MR Analysis of Tissue Composition (Preface-4.8)

- Category III CPT® codes for quantitative analysis of multiparametric-MR (mp-MRI) data with and without an associated diagnostic MRI have been established. Quantitative mp-MRI uses software to analyze tissue physiology of visceral organs and other anatomic structures non-invasively. At present, these procedures are primarily being used in clinical trials and there is no widely recommended indications in clinical practice. As such, these procedures are considered to be investigational and experimental for coverage purposes.
  - CPT® 0648T (without diagnostic MRI) and CPT® 0649T (with diagnostic MRI) refer to data analysis with and without associate imaging of a single organ, with its most common use being LiverMultiScan (LMS).
    - See Fatty Liver (AB-29.2) in the Abdomen Imaging Guidelines.
  - CPT® 0697T (without diagnostic MRI) and CPT® 0698T (with diagnostic MRI) refer to data analysis with and without associate imaging of a multiple organs, with its most common use being CoverScan.
HCPCS Codes (Preface-4.9)

PRF.CD.0004.9.A
v3.0.2023

- Healthcare Common Procedure Coding System (HCPCS) codes are utilized by some hospitals in favor of the typical Level-III CPT codes. These codes are typically 4 digits preceded by a C or S.
  - Many of these codes have similar code descriptions to Level-III CPT codes (i.e., C8931 – MRA with dye, Spinal Canal; and, CPT 72159 – MRA Spinal Canal).
  - If cases are submitted with HCPCS codes with similar code descriptions to the typical Level-III CPT codes, those procedures should be managed in the same manner as the typical CPT codes.
  - Medicare does not support approval of "S" HCPCS codes.
  - HCPCS code management is discussed further in the applicable guideline sections.

- Requests for many Healthcare Common Procedure Coding System (HCPCS) codes, including non-specific codes such as S8042 (Magnetic resonance imaging [MRI], low-field), should be redirected to a more appropriate and specific CPT code. Exceptions are noted in the applicable guideline sections.
2. Intraoperative MR. Brainlab. Available at: https://www.brainlab.com/surgery-products/overview-neurosurgery-products/intraoperative-mr/
Whole-Body Imaging (Preface-5)

Guideline | Page
--- | ---
Whole-Body CT Imaging (Preface-5.1) | 33
Whole-Body MR Imaging (Preface-5.2) | 34
PET-MRI (Preface-5.3) | 35
References (Preface-5) | 36
Whole-Body CT Imaging (Preface-5.1)

PRF.WB.0005.1.A
v3.0.2023

- Whole-body CT or LifeScan (CT Brain, Chest, Abdomen, and Pelvis) for screening of asymptomatic individuals is not a covered benefit of any of the current health plans who have delegated utilization review to eviCore. The performance of whole-body screening CT examinations in healthy individuals does not meet any of the current validity criteria for screening studies and there is no clear documentation of benefit versus radiation risk.

- Whole-body low-dose CT is supported for oncologic staging in Multiple Myeloma. See Multiple Myeloma and Plasmacytomas (ONC-25) in the Oncology Imaging Guidelines.
Whole-Body MR Imaging (Preface-5.2)

PRF.WB.0005.2.A
v3.0.2023

• Whole-body MRI (WBMRI) is, with the exception of select cancer predisposition syndromes and autoimmune conditions discussed below, generally not supported at this time due to lack of standardization in imaging technique and lack of evidence that WBMRI improves outcome for any individual disease state.
  - While WBMRI has the benefit of whole-body imaging and lack of radiation exposure, substantial variation still exists in the number of images, type of sequences (STIR vs. diffusion weighting, for example), and contrast agent(s) used.

• Coding considerations:
  - There are no established CPT® or HCPCS codes for reporting WBMRI.
  - WBMRI is at present only reportable using CPT® 76498. All other methods of reporting whole-body MRI are inappropriate including the following:
    - Separate diagnostic MRI codes for multiple individual body parts
    - MRI Bone Marrow Supply (CPT® 77084)

• Disease-specific considerations:
  - Cancer screening:
    - Interval WBMRI is recommended for cancer screening in individuals with select cancer predisposition syndromes. Otherwise, WBMRI has not been shown to improve outcomes for cancer screening.
      - For additional information, see Li-Fraumeni Syndrome (LFS) (PEDONC-2.2), Hereditary Paraganglioma-Pheochromocytoma (HPP) Syndromes (PEDONC-2.13), or Constitutional Mismatch Repair Deficiency (CMMRD or Turcot Syndrome) (PEDONC-2.15) in the Pediatric Oncology Imaging Guidelines.
  - Cancer staging and restaging:
    - While the feasibility of WBMRI has been established, data remain conflicting on whether WBMRI is of equivalent diagnostic accuracy compared with standard imaging modalities such as CT, scintigraphy, and PET imaging. Evidence has not been published establishing WBMRI as a standard evaluation for any type of cancer.

  - Autoimmune disease:
    - WBMRI can be approved in some situations for individuals with chronic recurrent multifocal osteomyelitis.
      - For additional information, see Chronic Recurrent Multifocal Osteomyelitis (PEDMS-10.2) in the Pediatric Musculoskeletal Imaging Guidelines.
PET-MRI (Preface-5.3)

**Preface to the Imaging Guidelines V3.0.2023**

**PET.WB.0005.3.A**

**v3.0.2023**

- PET-MRI is generally not supported for a vast majority of oncologic and neurologic conditions due to lack of standardization in imaging technique and interpretation. However, it may be appropriate in select circumstances when the following criteria are met:
  - The individual meets guideline criteria for PET-CT, **AND**
  - PET-CT is not available at the treating institution, **AND**
  - The provider requests PET-MRI in lieu of PET-CT

- When the above criteria are met, PET-MRI may be reported using the code combination of PET Whole-Body (CPT® 78813) and MRI Unlisted (CPT® 76498). All other methods of reporting PET-MRI are inappropriate.
  - When clinically appropriate, diagnostic MRI codes may be indicated at the same time as the PET-MRI code combination.

- For more information, see **PET Imaging in Pediatric Oncology (PEDONC-1.4)** in the Pediatric Oncology Imaging Guidelines, and **PET Brain Imaging (PEDHD-2.3)** and **Special Imaging Studies in Evaluation for Epilepsy Surgery (PEDHD-6.3)** in the Pediatric Head Imaging Guidelines.
References (Preface-5)


# References (Preface-6)

<table>
<thead>
<tr>
<th>Guideline</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>References (Preface-6.1)</td>
<td>38</td>
</tr>
</tbody>
</table>
References (Preface-6.1)

PRF.RF.0006.1.A
v3.0.2023

- Complete reference citations for the journal articles are embedded within the body of the guidelines and/or may be found on the Reference pages at the end of some guideline sections.
- The website addresses for certain references are included in the body of the guidelines but are not hyperlinked to the actual website.
- The website address for the American College of Radiology (ACR) Appropriateness Criteria® is http://www.acr.org.
## Copyright Information (Preface-7)

<table>
<thead>
<tr>
<th>Guideline</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Copyright Information (Preface-7.1)</td>
<td>.......................................................... 40</td>
</tr>
</tbody>
</table>
Copyright Information (Preface-7.1)

©2023 eviCore healthcare. All rights reserved. No part of these materials may be changed, reproduced, or transmitted in any form or by any means, electronic or mechanical, including photocopying or recording, or in any information storage or retrieval system, without the prior express written permission of eviCore.
<table>
<thead>
<tr>
<th>Guideline</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trademarks (Preface-8.1)</td>
<td>42</td>
</tr>
</tbody>
</table>
Trademarks (Preface-8.1)

- **CPT® (Current Procedural Terminology)** is a registered trademark of the American Medical Association (AMA). CPT® five digit codes, nomenclature, and other data are copyright 2023 American Medical Association. All Rights Reserved. No fee schedules, basic units, relative values, or related listings are included in the CPT® book. AMA does not directly or indirectly practice medicine or dispense medical services. AMA assumes no liability for the data contained herein or not contained herein.